These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 19855075

  • 1. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.
    Zagon IS, Rahn KA, Turel AP, McLaughlin PJ.
    Exp Biol Med (Maywood); 2009 Nov; 234(11):1383-92. PubMed ID: 19855075
    [Abstract] [Full Text] [Related]

  • 2. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
    Rahn KA, McLaughlin PJ, Zagon IS.
    Brain Res; 2011 Mar 24; 1381():243-53. PubMed ID: 21256121
    [Abstract] [Full Text] [Related]

  • 3. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
    Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ.
    Brain Res; 2010 Jan 15; 1310():154-61. PubMed ID: 19931226
    [Abstract] [Full Text] [Related]

  • 4. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD, Zagon IS, McLaughlin PJ.
    Exp Biol Med (Maywood); 2018 Feb 15; 243(4):361-369. PubMed ID: 29307283
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone.
    Ludwig MD, Zagon IS, McLaughlin PJ.
    Exp Biol Med (Maywood); 2017 Sep 15; 242(15):1524-1533. PubMed ID: 28766982
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes.
    Kerlero de Rosbo N, Mendel I, Ben-Nun A.
    Eur J Immunol; 1995 Apr 15; 25(4):985-93. PubMed ID: 7737302
    [Abstract] [Full Text] [Related]

  • 11. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis.
    Herrero-Herranz E, Pardo LA, Gold R, Linker RA.
    Neurobiol Dis; 2008 May 15; 30(2):162-73. PubMed ID: 18342527
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
    Garay L, Gonzalez Deniselle MC, Gierman L, Meyer M, Lima A, Roig P, De Nicola AF.
    Neuroimmunomodulation; 2008 May 15; 15(1):76-83. PubMed ID: 18667803
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets.
    Jagessar SA, Smith PA, Blezer E, Delarasse C, Pham-Dinh D, Laman JD, Bauer J, Amor S, 't Hart B.
    J Neuropathol Exp Neurol; 2008 Apr 15; 67(4):326-40. PubMed ID: 18379435
    [Abstract] [Full Text] [Related]

  • 16. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Noorbakhsh F, Tsutsui S, Vergnolle N, Boven LA, Shariat N, Vodjgani M, Warren KG, Andrade-Gordon P, Hollenberg MD, Power C.
    J Exp Med; 2006 Feb 20; 203(2):425-35. PubMed ID: 16476770
    [Abstract] [Full Text] [Related]

  • 17. Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells.
    Ellestad KK, Tsutsui S, Noorbakhsh F, Warren KG, Yong VW, Pittman QJ, Power C.
    J Immunol; 2009 Jul 01; 183(1):298-309. PubMed ID: 19542441
    [Abstract] [Full Text] [Related]

  • 18. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein.
    Lyons JA, Ramsbottom MJ, Cross AH.
    Eur J Immunol; 2002 Jul 01; 32(7):1905-13. PubMed ID: 12115610
    [Abstract] [Full Text] [Related]

  • 19. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.
    Göbel K, Pankratz S, Schneider-Hohendorf T, Bittner S, Schuhmann MK, Langer HF, Stoll G, Wiendl H, Kleinschnitz C, Meuth SG.
    J Autoimmun; 2011 Mar 01; 36(2):106-14. PubMed ID: 21216565
    [Abstract] [Full Text] [Related]

  • 20. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery.
    Samoilova EB, Horton JL, Chen Y.
    Cell Immunol; 1998 Sep 15; 188(2):118-24. PubMed ID: 9756642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.